Gemcitabine, Cisplatin, and Durvalumab Combination Toxicities

Hematologic Toxicities

Neutropenia occurs in 53% of patients (grade 3-4), with nadirs typically at 7-14 days after each cycle and recovery by day 21 1, 2
Thrombocytopenia affects 19% of patients (grade 3-4), following similar temporal patterns with nadirs at 7-14 days 2
Complete blood counts must be obtained before each cycle and at days 8 and 15 when using this regimen 2
Dose modifications are required when absolute neutrophil count falls below 1,500/μL or platelets below 100,000/μL 2

Diarrhea is more frequent with immunotherapy addition (risk ratio 1.19, 95% CI 1.13-1.26) compared to chemotherapy alone 3
Vomiting increases with combination therapy (risk ratio 1.12, 95% CI 1.05-1.19) 3
Pneumonitis risk increases 2.79-fold (95% CI 2.09-3.74) when adding immunotherapy to chemotherapy compared to chemotherapy alone 3, 2
Thyroid dysfunction (risk ratio 2.13, 95% CI 1.90-2.40) is the most common endocrinopathy 3
Hepatotoxicity with elevated liver enzymes (risk ratio 1.13, 95% CI 1.06-1.20) 3
Rash occurs in >20% of patients and is 1.56 times more frequent with immunotherapy (95% CI 1.44-1.70) 3
Nephritis with creatinine increase (risk ratio 1.34, 95% CI 1.21-1.48) 3
Peripheral neuropathy is modestly increased (risk ratio 1.14, 95% CI 1.07-1.21) 3

Days 1-21 of each cycle: Monitor CBC at baseline, day 8, and day 15 for hematologic nadirs 2
Months 1-6: Highest risk period for pneumonitis; educate patients to report dyspnea, cough, or chest pain immediately 2
Any time: New respiratory symptoms warrant immediate chest CT to exclude pneumonitis 2
The addition of immunotherapy increases all-grade adverse events (risk ratio 1.11, 95% CI 1.09-1.12) without increasing mortality 3